Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,972,560
  • Shares Outstanding, K 2,354,800
  • Annual Sales, $ 18,291 M
  • Annual Income, $ 5,839 M
  • 60-Month Beta 0.44
  • Price/Sales 8.64
  • Price/Cash Flow 23.77
  • Price/Book 16.65
Trade NVO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.60
  • Number of Estimates 3
  • High Estimate 0.64
  • Low Estimate 0.57
  • Prior Year 0.55
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.43 +4.78%
on 11/02/20
72.03 -6.28%
on 11/06/20
+3.62 (+5.67%)
since 10/30/20
3-Month
63.22 +6.79%
on 10/30/20
73.81 -8.54%
on 10/12/20
+1.62 (+2.46%)
since 09/01/20
52-Week
49.24 +37.10%
on 03/20/20
73.81 -8.54%
on 10/12/20
+11.36 (+20.23%)
since 11/29/19

Most Recent Stories

More News
Ocular Drug Delivery Technology Market : Technological Advancements to Play a Key Role in Growth 2020-2029 | Alimera Sciences Inc, Valeant Pharmaceuticals International Inc

A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2029 by discloses a succinct analysis of the regional spectrum,...

ALIM : 4.60 (-1.92%)
AGN : 193.02 (+0.02%)
AAPL : 122.72 (+3.08%)
CLSD : 1.9100 (-4.98%)
DYAI : 6.19 (+5.63%)
NVS : 90.72 (-0.12%)
NVO : 67.51 (+0.57%)
OCUL : 17.96 (+2.63%)
PFE : 39.41 (+2.87%)
VRX.TO : 30.80 (-3.33%)
AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure

AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.

JNJ : 147.45 (+1.91%)
NVO : 67.51 (+0.57%)
AZN : 52.98 (+0.08%)
LLY : 145.56 (-0.06%)
Is Novo Nordisk (NVO) a Suitable Stock for Value Investors?

Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

NVO : 67.51 (+0.57%)
13th Annual Biotech Showcase(TM) to Bring Together Attendees Digitally in 2021 for Investing, Partnering and Collaboration

Biotech Showcase(TM) Digital is the investor conference that drives the future of biotech innovation, digital medicine, and international collaboration. In its 13th year, the conference will be a virtual...

NVO : 67.51 (+0.57%)
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint

Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.

NVO : 67.51 (+0.57%)
ALIM : 4.60 (-1.92%)
ABEO : 1.5200 (-6.17%)
ASLN : 1.6300 (-4.68%)
EMISPHERE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emisphere Technologies, Inc. - EMIS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Emisphere Technologies, Inc. (OTC: EMIS) to Novo...

EMIS : 7.8000 (+0.26%)
NVO : 67.51 (+0.57%)
Novo Nordisk Thailand certified as a "Best Place To Work" in 2020

Novo Nordisk Thailand, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been recognized as one of the best companies to work in Thailand...

NVO : 67.51 (+0.57%)
Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial

Bagsvaerd, Denmark, 17 November 2020 - Novo Nordisk today announced headline results from the SUSTAIN FORTE trial, a phase 3b 40-week, efficacy and safety trial with once-weekly semaglutide 2.0 mg vs once-weekly...

NVO : 67.51 (+0.57%)
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

NVO : 67.51 (+0.57%)
GILD : 61.12 (+0.74%)
GLMD : 3.84 (-0.26%)
ICPT : 35.69 (+0.51%)
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

- Company to receive upfront payment of EUR5 million replacing a later stage regulatory approval milestone of U.S.$5 million

NVO : 67.51 (+0.57%)
AEZS : 0.3950 (-1.05%)
AEZS.TO : 0.52 (+1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 68.27
1st Resistance Point 67.89
Last Price 67.51
1st Support Level 66.94
2nd Support Level 66.37

See More

52-Week High 73.81
Last Price 67.51
Fibonacci 61.8% 64.42
Fibonacci 50% 61.53
Fibonacci 38.2% 58.63
52-Week Low 49.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar